BMI1P1 and acute myeloid leukemia: Kaplan–Meier demonstrated that patients with low-expressed BMI1P1 had significantly shorter leukemia free survival (LFS, median 0 vs 6.5 months, respectively, P = 0.002) and overall survival (OS, median 5 vs 13 months, respectively, P < 0.001) than BMI1P1 high-expressed patients in the whole cohort of AML patients (Figure 4A, 4B).